These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 7482403

  • 1. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE.
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [Abstract] [Full Text] [Related]

  • 2. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
    Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P.
    Blood; 1992 Feb 01; 79(3):568-75. PubMed ID: 1531035
    [Abstract] [Full Text] [Related]

  • 3. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM.
    Thromb Haemost; 1993 Nov 15; 70(5):768-73. PubMed ID: 8128433
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
    Shapiro AD, Ragni MV, Lusher JM, Culbert S, Koerper MA, Bergman GE, Hannan MM.
    Thromb Haemost; 1996 Jan 15; 75(1):30-5. PubMed ID: 8713776
    [Abstract] [Full Text] [Related]

  • 5. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J, Peynet J, Chambost H, Négrier C, Briquel ME, Claeyssens S, Derlon-Borel A, Guérois C, Caron C, Scherrmann JM, Debray M, Bridey F.
    Thromb Haemost; 1998 Dec 15; 80(6):919-24. PubMed ID: 9869161
    [Abstract] [Full Text] [Related]

  • 6. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E, Mannucci PM, Gringeri A, Tagariello G, Baudo F, Bauer KA, Rosenberg RD.
    Thromb Haemost; 1994 Jun 15; 71(6):737-40. PubMed ID: 7974341
    [Abstract] [Full Text] [Related]

  • 7. Heat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.
    Benny AG, Ockelford PA, Johns AS, Woodfield DG, Berry EW.
    N Z Med J; 1986 Jun 11; 99(803):408-9. PubMed ID: 3461352
    [Abstract] [Full Text] [Related]

  • 8. Safety and recovery of mononine in multiple-dose, high-dose regimens.
    White GC.
    Acta Haematol; 1995 Jun 11; 94 Suppl 1():53-7; discussion 57-8. PubMed ID: 7571996
    [Abstract] [Full Text] [Related]

  • 9. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies.
    Mauser-Bunschoten EP, Kleine Budde I, Lopaciuk S, Koopman MM, Van Der Meer FJ, Novàkovà IR, Ypma P, Van Der Linden PW, Windyga J, Strengers PF.
    Haemophilia; 2011 May 11; 17(3):439-45. PubMed ID: 21362109
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
    Djulbegovic B, Marasa M, Pesto A, Kushner GM, Hadley T, Joseph G, Goldsmith G.
    Am J Hematol; 1996 Feb 11; 51(2):168-70. PubMed ID: 8579061
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study.
    Poon MC, Lillicrap D, Hensman C, Card R, Scully MF.
    Thromb Haemost; 2002 Mar 11; 87(3):431-5. PubMed ID: 11916075
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A, Hong A, Arguello A, Echenagucia M, Boadas A, Fabbrizzi F, Minichilli F, Bosch NB.
    Haemophilia; 2005 Nov 11; 11(6):583-8. PubMed ID: 16236107
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañes M, Paez A.
    Haemophilia; 2010 Mar 11; 16(2):240-6. PubMed ID: 20015218
    [Abstract] [Full Text] [Related]

  • 20. Surgical operation in hemophilia B. Use of factor IX concentrate.
    Kasper CK.
    Calif Med; 1970 Jul 11; 113(1):4-8. PubMed ID: 5520728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.